On Dec 8, 2018 Acelrx Pharmaceuticals Inc (NASDAQ:ACRX) Shorts Rose By 1.48%

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Corporate Logo

Big Money Sentiment increased to 1.22 in Q2 2018. It has change of 0.15, from 2018Q1’s 1.07. The ratio increased due to AcelRx Pharmaceuticals, Inc. positioning: 7 sold and 11 reduced. 9 funds acquired positions and 13 increased positions. Investors holded 4.27 million in 2018Q1 but now own 4.49 million shares or 5.17% more.
Invesco Ltd has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Moreover, Citadel Advisors Limited Liability has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 119,363 shs. Morgan Stanley holds 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) or 29,942 shs. Bridgeway Capital Mngmt invested 0.01% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Burt Wealth Advsr holds 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) or 1,000 shs. Jpmorgan Chase & reported 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Wells Fargo And Mn reported 31,003 shs. Manufacturers Life Company The owns 362 shs for 0% of their capital. Hrt Ltd Liability Com owns 0.02% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 15,990 shs. Barclays Public Limited Company accumulated 3,400 shs. State Street Corp invested in 47,400 shs or 0% of the stock. D E Shaw Inc invested in 0% or 249,992 shs. Bankshares Of Mellon owns 44,003 shs for 0% of their capital. New York-based Joel Isaacson Limited Liability Company has invested 0.01% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Credit Suisse Ag holds 0% of its capital in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 14,008 shs.

AcelRx Pharmaceuticals, Inc. registered $75,982 net activity with 3 insider buys and 3 selling transactions since September 24, 2018. On Monday, October 15 Hamel Lawrence G sold $26,080 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Another trade for 5,000 shs valued at $15,646 was made by ASADORIAN RAFFI on Tuesday, November 13. The insider EDWARDS MARK G bought $58,376. On Monday, October 15 $141,755 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was sold by Dasu Badri N.

It was showed an increase on Acelrx Pharmaceuticals Inc (NASDAQ:ACRX)’s shares shorted with 1.48%. In December was issued ACRX’s total 3.25M shares shorted by FINRA. That’s 1.48% up from 3.21 million shares. Acelrx Pharmaceuticals Inc (NASDAQ:ACRX) has 469,100 shares average volume. It’ll cost 7 days for ACRX to restore its previous position.

The stock increased 3.07% or $0.1 during the last trading session, hitting $3.36.AcelRx Pharmaceuticals, Inc. has volume of 1.61M shares. Since December 8, 2017 ACRX has risen 1.54% and is uptrending. The stock underperformed the S&P500 by 14.08%.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.The firm is valued at $256.68 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain.Currently it has negative earnings. The companyÂ’s late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Ratings Coverage

Total analysts of 5 have positions in AcelRx Pharmaceuticals (NASDAQ:ACRX) as follows: 4 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 80%. Since June 12, 2018 according to StockzIntelligence Inc AcelRx Pharmaceuticals has 6 analyst reports. In Wednesday, October 10 report Ladenburg Thalmann maintained the stock with “Buy” rating. The company rating was upgraded by Jefferies on Monday, October 15.

For more AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) news brought out recently go to: Fool.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “3 Stocks to Hold for the Next 20 Years – The Motley Fool” brought out on December 01, 2018, “AcelRx Pharmaceuticals Gets A Thumbs Up From Advisory Committee – Seeking Alpha” on October 16, 2018, “AcelRx Will Go It Alone With Dsuvia, But The Future Looks Bright – Seeking Alpha” with a publish date: November 14, 2018, “AcelRx Finally Has An AdCom Date. Time For A Run Up? – Seeking Alpha” and the last “Health Care Sector Update for 11/09/2018: JAZZ,ACRX,ACET,NTRA – Nasdaq” with publication date: November 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.